Search Result

Pathways Recommended:	Stem Cell/Wnt

Results for "

WNT target gene

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Wnt (14) Akt (1) Apoptosis (3) Bcl-2 Family (2) c-Myc (3) CDK (1) COX (1) EGFR (1) Endogenous Metabolite (1) ERK (1) GSK-3 (1) Interleukin Related (1) JNK (1) LPL Receptor (1) MAP4K (1) PPAR (1) Reference Standards (1) Smo (1) Survivin (1) β-catenin (8)
By Research Areas:	Cancer (14) Cardiovascular Disease (1) Inflammation/Immunology (2) Metabolic Disease (2)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Targets Recommended: Wnt LAG-3 CGRP Receptor MALT1 Dan family RIG-I-like receptor (RLR) NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-120697

MSAB Maximum Cited Publications 50 Publications Verification	Wnt β-catenin	Cancer
MSAB is a potent and selective inhibitor of *Wnt/β-catenin* signaling. MSAB binds to β-catenin and promotes its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells .

HY-124745

KY-05009 1 Publications Verification	MAP4K Wnt Apoptosis	Cancer
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a K_i of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of *Wnt* target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity .

HY-12316

20(S)-Hydroxycholesterol 3 Publications Verification 20α-Hydroxycholesterol	Smo Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC₅₀ of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the Raf/MEK/ERK pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis .

HY-172920

Wnt/β-catenin-IN-6	Wnt β-catenin EGFR ERK COX Akt GSK-3 c-Myc Apoptosis Interleukin Related JNK	Inflammation/Immunology Cancer
Wnt/β-catenin-IN-6 is an orally active *Wnt/β-catenin* pathway inhibitor. Wnt/β-catenin-IN-6 blocks the AKT/GSK-3β/β-catenin signaling pathway, leading to reduced expression of Wnt target genes (c-Myc, c-Jun). Wnt/β-catenin-IN-6 reduces COX2 expression and IL-8 levels, highlighting its dual anti-inflammatory and antitumor effects. Wnt/β-catenin-IN-6 can induce apoptosis. Wnt/β-catenin-IN-6 serves as a tool for non-small cell lung cancer (NSCLC) research .

HY-108442

JW67 1 Publications Verification	Wnt	Cancer
JW67 inhibits the canonical *Wnt* signaling with an IC₅₀ of 1.17μM . JW67 affects the multiprotein complex consisting of β-catenin/GSK-3β/AXIN/APC/CK1 that rapidly reduces active β-catenin with a subsequent downregulation of *Wnt* target genes. JW67 also inhibits colorectal cancer cell growth .

HY-119966

CCT036477	Wnt β-catenin PPAR CDK	Cancer
CCT036477 is a *Wnt/β-catenin* pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2) .

HY-W010995

2,5-Dimethylcelecoxib	Wnt Survivin β-catenin	Cancer
2,5-Dimethylcelecoxib is an analogue of celecoxib (HY-14398) with anticancer activity but without COX-2 inhibitory activity. 2,5-Dimethylcelecoxib exerts its anti-cancer cell proliferation effect by inhibiting the core mechanism of the *Wnt/β-catenin* signaling pathway. 2,5-Dimethylcelecoxib also inhibits T-cell factor-dependent transcriptional activity and inhibits expression of the Wnt/β-catenin target gene products cyclin D1 and survivin .

HY-148918

E722-2648	β-catenin Wnt Bcl-2 Family	Inflammation/Immunology Cancer
E722-2648 is an inhibitor targeting the BCL9 and β-catenin complex with antitumor activity. E722-2648 blocks complex formation by disrupting the interaction between the two proteins, thereby inhibiting β-catenin-mediated transcriptional activity and downregulating the expression of *WNT* target genes. E722-2648 effectively inhibits tumor growth in colon cancer xenograft models and colorectal cancer mouse models. E722-2648 can be used for the research of colon cancer and colorectal cancer .

HY-P991311

GSK3178022	LPL Receptor Wnt	Cancer
GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of *WNT* target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-148918A

E722-2648 TFA	β-catenin Wnt Bcl-2 Family	Cancer
E722-2648 TFA is an inhibitor targeting the BCL9 and β-catenin complex with antitumor activity. E722-2648 TFA blocks complex formation by disrupting the interaction between the two proteins, thereby inhibiting β-catenin-mediated transcriptional activity and downregulating the expression of *WNT* target genes. E722-2648 TFA effectively inhibits tumor growth in colon cancer xenograft models and colorectal cancer mouse models. E722-2648 TFA can be used for the research of colon cancer and colorectal cancer .

HY-149858

β-catenin-IN-7	Wnt	Cancer
β-catenin-IN-7 (Compound 9) is a β-catenin inhibitor. β-catenin-IN-7 inhibits the interaction between β-catenin and Tcf-4, and inhibits Wnt-dependent target gene expression. β-catenin-IN-7 has anti-cancer activity .

HY-169348

β-catenin-IN-8	β-catenin Wnt c-Myc	Cancer
β-catenin-IN-8 (Compound 25) is a β-catenin inhibitor. β-catenin-IN-8 inhibits β-catenin and c-Myc protein levels, and inhibits *Wnt*-target genes level (Fgf20 and Sall4). β-catenin-IN-8 has colorectal cancer anticancer activities, and has metabolic stability .

HY-181560

SLD1121	Wnt β-catenin	Metabolic Disease
SLD1121 is an agonist of the *Wnt/β-catenin* signaling pathway that enhances *Wnt* signaling by targeting LRP6 (K_d: 4.52-7.49 nM). SLD1121 interacts with the intracellular domain of LRP6, stabilizes LRP6, promotes its nuclear translocation, and facilitates its binding to β-catenin, TCF4 or LEF1 in the nucleus, thereby inducing the expression of *Wnt*-regulated genes and stem cell-related genes. SLD1121 induces the transition of hair follicles from telogen to anagen in the mouse hair growth cycle and promotes hair growth in mice. SLD1121 is applicable to hair loss-related research .

HY-108442R

JW67 (Standard)	Reference Standards Wnt	Cancer
JW67 (Standard) is the analytical standard of JW67 (HY-108442). This product is intended for research and analytical applications. JW67 inhibits the canonical Wnt signaling with an IC₅₀ of 1.17μM . JW67 affects the multiprotein complex consisting of β-catenin/GSK-3β/AXIN/APC/CK1 that rapidly reduces active β-catenin with a subsequent downregulation of Wnt target genes. JW67 also inhibits colorectal cancer cell growth .

HY-181930

TNIK-IN-10	Wnt c-Myc Apoptosis	Cancer
TNIK-IN-10 (Compound N15) is a TNIK inhibitor with an IC₅₀ of 0.49 nM against human TNIK. TNIK-IN-10 inhibits the enzymatic activity of TNIK, downregulates the expression of *Wnt* pathway target genes c-Myc and AXIN2, and reduces the protein expression of LRP5 and LRP6. TNIK-IN-10 induces apoptosis. TNIK-IN-10 exhibits anticancer activity against colorectal cancer. TNIK-IN-10 can be used in the research of colorectal cancer .

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library	2,522 compounds
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,522 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Anti-Colorectal Cancer Compound Library

2,522 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,522 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area	Image

HY-P991311

GSK3178022	LPL Receptor Wnt	Cancer
GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of *WNT* target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-12316

20(S)-Hydroxycholesterol 3 Publications Verification 20α-Hydroxycholesterol	Classification of Application Fields Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	Smo Endogenous Metabolite
20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC₅₀ of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the Raf/MEK/ERK pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks